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INHIBITION OF SMOOTH MUSCLE CELL PROLIFERATION AND INTIMAL THICKENING WITH SMALL 
PEPTIDE MIMETICS OF SOLUBLE NCADHERIN  
Cressida Lyon, Sandra Medina-Villar, Imke Sittel, Alexandra Wasmuth, Carmen Galan, Sarah George.  
University of Bristol, Bristol, United Kingdom  
Aim: We investigated whether a small peptide sequence from soluble Ncadherin (SNC) modulated 
intimal thickening by changing vascular smooth muscle cell (VSMC),fibroblast and endothelial cell 
(EC) behaviour. Restenosis of vein grafts is a significant problem resulting in failure in 30-50% of 
patients. Reduction of VSMC proliferation, without preventing re-endothelialisation is desirable. SNC 
reduced ex vivo intimal thickening and increased endothelial coverage. We wish to produce a 
smaller therapeutic peptide. Methods: Cells: Human saphenous vein VSMC and fibroblasts; HUVECs. 
Proliferation: EdU incorporation. Migration: scratch wound assay (distance migrated, mm). 
Apoptosis: cleaved caspase-3 immunocytochemistry. Human saphenous vein organ culture used as 
ex vivo model of intimal thickening, analysed by elastin van Gieson staining (intimal size), EdU 
(proliferation) and Q-Bend-10 (endothelial coverage). Results: The peptide significantly reduced 
VSMC proliferation (14.4±4.8% vs 3.58±2.2%, n¼4, p<0.05). Conclusions: A peptide mimetic of SNC is 
an attractive therapeutic for restenosis as it attenuates VSMC proliferation, without detrimental 
effects on re-endothelialisation. A peptide is inexpensive to produce and easy to deliver. 
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